FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. PMID 42373605 · Blood Cancer J · 2026-Jun-29 The report is a secondary analysis of an observational database, not the primary report of a randomized controlled trial. While it discusses a randomized Phase III trial (VERONA) for context, the analysis presented is of non-randomized treatment groups (HMA monotherapy vs HMA/VEN) from a real-world cohort. Therefore, it does not meet the requirement for an original formal-result report of a randomized trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. PMID 42373197 · BMJ Open Ophthalmol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Chinese herbal medicine Xiangsu Hewei Granules in treating non-erosive gastroesophageal reflux disease with liver stomach stagnation heat syndrome: A multicentre, randomized, double-blind, placebo-controlled trial. PMID 42372807 · J Ethnopharmacol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial. PMID 42372782 · Lancet Rheumatol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Protocol for a phase 3, randomized, double-blind clinical trial evaluating the safety and immunogenicity of the MVA-BN® vaccine against mpox in children aged 4 to less than 24 months in the Democratic Republic of the Congo: Data to guide future paediatric vaccination strategies. PMID 42372625 · Vaccine · 2026-Jun-29 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants. PMID 42371393 · Eur J Drug Metab Pharmacokinet · 2026-Jun-29 The study is a Phase 1, randomized, open-label, crossover pharmacokinetic/bioequivalence study in healthy adults. Although it involves an oncology drug (vepdegestrant) for a cancer indication, the trial is Phase I, the primary endpoints are pharmacokinetic (AUC, Cmax), and it does not assess time-to-event efficacy outcomes (e.g., OS, PFS, DFS, HR, Kaplan-Meier) in cancer patients. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort of definitive efficacy trials. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01). PMID 42370451 · J Hepatobiliary Pancreat Sci · 2026-Jun-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial. PMID 41151803 · Stroke Vasc Neurol · 2026-Jun-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial. PMID 42364816 · Radiother Oncol · 2026-Jun-27 干预为非药物单独策略,未满足药物干预要求。 |
H
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| JAAD Game Changers: "Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial". PMID 42364776 · J Am Acad Dermatol · 2026-Jun-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial. PMID 42363777 · Int J Cancer · 2026-Jun-27 The record does not meet all eligibility criteria: while it is an oncology-related, human, randomized trial with a time-to-event endpoint and original results, it lacks a drug-containing intervention and explicit Phase III/IIIb or Phase II/III evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. PMID 42330995 · Lancet · 2026-Jun-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. PMID 42218899 · Lancet · 2026-Jun-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. PMID 42214392 · Lancet · 2026-Jun-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial. PMID 42363252 · Int J Retina Vitreous · 2026-Jun-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immersive virtual reality with synchronous neurostimulation for upper-limb recovery after stroke: a randomized feasibility trial. PMID 42362865 · Nat Med · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events. PMID 42362563 · NPJ Breast Cancer · 2026-Jun-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Beyond the "cold" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer. PMID 42362076 · Crit Rev Oncol Hematol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial. PMID 42361317 · Eur J Heart Fail · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. PMID 42361282 · J Clin Oncol · 2026-Jun-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial. PMID 42361276 · J Clin Oncol · 2026-Jun-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial. PMID 42360803 · Clin Cancer Res · 2026-Jun-26 This is a pre-specified biomarker subgroup analysis of the ENZAMET trial, not the primary result report of the randomized Phase III trial itself. The primary trial results are reported elsewhere. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Global Trends in Surgical Oncology Deescalation Phase III Randomized Trials. PMID 42360646 · Ann Surg Oncol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study. PMID 42360473 · J Neurol · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. PMID 42360104 · Clin Cancer Res · 2026-Jun-26 The record reports a secondary analysis (identifying variables associated with early detriment) from two Phase III randomized trials (CheckMate 227 and 9LA). While the underlying trials are eligible, this specific publication is not a primary report of an original efficacy endpoint. The abstract focuses on rapid progression rates and biomarker associations, not on presenting Kaplan-Meier survival curves or hazard ratios for the primary trial endpoints. Therefore, it does not meet the criterion of being an original formal-result report with a primary/key secondary time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient-led, home-based follow-up for colorectal cancer: the DISTANCE multicentre stepped-wedge cluster-randomised trial. PMID 42359543 · Br J Surg · 2026-Jun-26 The record is an oncology, human, randomized trial with results, but it is excluded because it is not a Phase III/IIIb or definitive Phase II/III trial, does not contain a drug-containing intervention (it is a non-drug follow-up model comparison), and does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint was hospital contacts, and secondary endpoints included QoL and distress metrics. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO). PMID 42357986 · Am J Clin Oncol · 2026-Jun-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning. PMID 42348666 · Curr Opin Hematol · 2026-Jun-26 The record is a journal article review article (publication_type: Journal Article) summarizing mechanistic and clinical data on factor XIa inhibitors. It is not an original result report of a Phase III/IIIb or Phase II/III randomized trial. The review mentions oncology (cancer-associated thrombosis) as a potential indication, but does not report results of an oncology trial with a time-to-event efficacy endpoint. It does not contain original Kaplan-Meier data, HR, or other time-to-event results for an oncology indication. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach. PMID 42330156 · Am J Clin Oncol · 2026-Jun-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Para-Aortic Lymph Node Staging and Oncologic Outcomes in Locally Advanced Cervical Cancer: A Narrative Review. PMID 42449603 · Cancers (Basel) · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis. PMID 42442095 · Eur J Cancer · 2026-Jun-25 The record is a cross-sectional review/meta-analysis of multiple trials, not an original primary report of a single trial. Therefore, it is excluded. |
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32. PMID 42360727 · JNCI Cancer Spectr · 2026-Jun-25 The record describes a secondary/prognostic biomarker analysis within a large randomized trial (MA.32). While the trial itself may be a definitive Phase III study, the specific report provided does not explicitly state the trial phase, and its primary focus is not on evaluating a drug intervention's efficacy but on the prognostic value of CA 15-3. Therefore, it fails the 'drug intervention' and 'explicit phase' criteria for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials. PMID 42351343 · Arthritis Rheumatol · 2026-Jun-25 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Strengthening cancer prevention in european schools: a randomized controlled trial of digital interventions in adolescents: the SUNRISE program. PMID 42351094 · BMC Public Health · 2026-Jun-25 The record describes a protocol for a cluster-randomized controlled trial of a digital health intervention for cancer prevention in adolescents. It is not a report of a completed Phase II/III or Phase III/IIIb randomized trial in human malignant neoplasm patients with a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trials. PMID 42350183 · Ann Rheum Dis · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A multicenter randomized controlled trial comparing metallic stents with 10- versus 14-mm diameter for distal biliary obstruction caused by unresectable pancreatic carcinoma. PMID 42349763 · Gastrointest Endosc · 2026-Jun-25 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial. PMID 42349245 · ESMO Open · 2026-Jun-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 1 Figure · 1 Panel · risk unclear |
| Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. PMID 42349017 · Blood Adv · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials. PMID 42348366 · Diabetes Obes Metab · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. PMID 42347868 · Clin Cancer Res · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment. PMID 42343061 · Eur J Clin Pharmacol · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. PMID 42341302 · N Engl J Med · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis. PMID 42341301 · N Engl J Med · 2026-Jun-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. PMID 42206582 · N Engl J Med · 2026-Jun-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial. PMID 42202479 · Eur J Cancer · 2026-Jun-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Potassium-competitive acid blockers for erosive reflux disease and stress ulcer prophylaxis: a narrative review. PMID 42084149 · Pol Arch Intern Med · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade. PMID 41999744 · Cell · 2026-Jun-25 The record describes a secondary, exploratory biomarker analysis (gut microbiome and recurrence) from a Phase III randomized trial (CheckMate 915). While it reports on recurrence-free survival (a time-to-event endpoint) in a drug-intervention trial, it is not the primary or key secondary efficacy report of the original trial's results. The analysis is a subgroup/post-hoc biomarker study, not the formal report of the trial's primary or pre-specified secondary efficacy outcomes (e.g., overall survival or the primary comparison of nivolumab+ipilimumab vs nivolumab for recurrence-free survival). Therefore, it is excluded as not being an original formal-result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy. PMID 41849227 · Blood · 2026-Jun-25 The trial is a Phase III randomized trial in oncology patients (AML/MDS) with time-to-event endpoints. However, the intervention is for GVHD prophylaxis using immunosuppressive agents (ATG, cyclophosphamide) in the transplant setting, not as a primary anticancer drug therapy. Therefore, it does not meet the criterion of a drug-containing intervention for treating malignant neoplasm. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improving basal cell carcinoma subtype diagnosis with dermoscopy and reflectance confocal microscopy: a multicentre prospective study. PMID 41685950 · Clin Exp Dermatol · 2026-Jun-25 The record describes a prospective diagnostic accuracy study for noninvasive imaging of basal cell carcinoma subtypes, not a randomized drug trial. It lacks a drug intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and is not a Phase III or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial. PMID 42396282 · medRxiv · 2026-Jun-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |